User login
Article Type
Changed
Fri, 01/18/2019 - 12:45
Display Headline
New data on Radium 223 presented at ASCO
CHICAGO – Dr. Nicholas Vogelzang, investigator on the ALSYMPCA trial, discusses new data on Radium 223 (Xofigo) and new research on castration-resistant metastatic prostate cancer at the ASCO Annual Meeting 2013.
Legacy Keywords
ASCO, American Society of Clinical Oncology, Radium 223, prostate cancer, Xofigo, Dr. Nicholas Vogelzang, ALSYMPCA
CHICAGO – Dr. Nicholas Vogelzang, investigator on the ALSYMPCA trial, discusses new data on Radium 223 (Xofigo) and new research on castration-resistant metastatic prostate cancer at the ASCO Annual Meeting 2013.
CHICAGO – Dr. Nicholas Vogelzang, investigator on the ALSYMPCA trial, discusses new data on Radium 223 (Xofigo) and new research on castration-resistant metastatic prostate cancer at the ASCO Annual Meeting 2013.
Article Type
Display Headline
New data on Radium 223 presented at ASCO
Display Headline
New data on Radium 223 presented at ASCO
Legacy Keywords
ASCO, American Society of Clinical Oncology, Radium 223, prostate cancer, Xofigo, Dr. Nicholas Vogelzang, ALSYMPCA
Legacy Keywords
ASCO, American Society of Clinical Oncology, Radium 223, prostate cancer, Xofigo, Dr. Nicholas Vogelzang, ALSYMPCA
Article Source
AT THE ASCO ANNUAL MEETING 2013
PURLs Copyright
Inside the Article